CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research note released on Monday morning. The firm issued a sell rating on the stock.

CEL-SCI Price Performance

CVM stock opened at $0.51 on Monday. The firm has a market cap of $38.00 million, a price-to-earnings ratio of -1.07 and a beta of 0.69. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. CEL-SCI has a 12-month low of $0.33 and a 12-month high of $2.50. The company’s fifty day simple moving average is $0.48 and its 200 day simple moving average is $0.78.

Hedge Funds Weigh In On CEL-SCI

Institutional investors have recently added to or reduced their stakes in the business. Calton & Associates Inc. acquired a new position in shares of CEL-SCI during the 3rd quarter valued at $50,000. Plotkin Financial Advisors LLC acquired a new position in shares of CEL-SCI during the third quarter valued at about $98,000. Thoroughbred Financial Services LLC raised its holdings in shares of CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after purchasing an additional 54,900 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares during the period. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.